Seeking Alpha

Can-Fite BioPharma rallies on rheumatoid arthritis data

  • Can-Fite BioPharma (CANF) jumps 18% in premarket action.
  • The company says a Phase 2b study of the A3AR agonist CF101 in RA "met all primary efficacy endpoints."
  • ACR20 response rates: CF101, 49%; placebo, 25%; p=0.035.
  • Responses were cumulative, indicating "a consistent anti-inflammatory effect."
  • The company calls the treatment's safety profile "excellent." (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: